Exane BNP Paribas began coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued on Thursday, The Fly reports. The brokerage set an "outperform" rating and a $330.00 price target on the biotechnology company's stock. Exane BNP Paribas' price target points to a potential upside of 26.17% from the stock's current price.
Several other research firms have also weighed in on RGEN. Stephens upped their price objective on shares of Repligen from $255.00 to $290.00 and gave the company an "overweight" rating in a research note on Friday, August 20th. BNP Paribas started coverage on shares of Repligen in a research note on Thursday. They issued an "outperform" rating and a $330.00 price objective on the stock. Zacks Investment Research lowered shares of Repligen from a "buy" rating to a "hold" rating and set a $305.00 price objective on the stock. in a research note on Tuesday, September 28th. Craig Hallum upped their price objective on shares of Repligen from $258.00 to $368.00 and gave the company a "buy" rating in a research note on Monday, September 27th. Finally, KeyCorp boosted their target price on shares of Repligen from $255.00 to $335.00 and gave the stock an "overweight" rating in a research report on Friday, September 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $306.00.
Shares of RGEN stock traded up $8.55 during trading hours on Thursday, reaching $261.56. 1,551 shares of the stock traded hands, compared to its average volume of 388,519. Repligen has a 1-year low of $162.29 and a 1-year high of $327.32. The business has a fifty day moving average price of $278.91 and a 200 day moving average price of $227.01. The firm has a market capitalization of $14.36 billion, a PE ratio of 146.31 and a beta of 0.90.
Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Monday, July 26th. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.52 by $0.27. The business had revenue of $162.96 million for the quarter, compared to analyst estimates of $144.24 million. Repligen had a net margin of 19.65% and a return on equity of 9.21%. The firm's revenue was up 86.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.42 earnings per share. As a group, analysts forecast that Repligen will post 2.76 earnings per share for the current year.
In other news, Director Karen A. Dawes sold 4,585 shares of the stock in a transaction on Tuesday, July 20th. The shares were sold at an average price of $202.09, for a total value of $926,582.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt sold 25,000 shares of the stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $294.75, for a total transaction of $7,368,750.00. Following the completion of the transaction, the chief executive officer now owns 214,495 shares of the company's stock, valued at approximately $63,222,401.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,154 shares of company stock valued at $14,144,680. 1.20% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. RPg Family Wealth Advisory LLC acquired a new stake in shares of Repligen during the 2nd quarter worth about $27,000. Creative Financial Designs Inc. ADV grew its holdings in Repligen by 50.0% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 50 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Repligen during the 2nd quarter worth about $37,000. Rational Advisors LLC bought a new stake in Repligen during the 2nd quarter worth about $48,000. Finally, Huntington National Bank grew its holdings in Repligen by 45.5% during the 2nd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $58,000 after acquiring an additional 91 shares during the last quarter. Institutional investors and hedge funds own 83.82% of the company's stock.
Repligen Company Profile
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
Further Reading: How to read a candlestick chart
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here